The fifth ELRIG meeting on Advances in Cell Based Screening in Drug Discovery will be held on May 15-16 at the AstraZeneca R&D site in Gothenburg. This interactive 2-day event will host leading scientists from academia, industry and the vendor community to discuss current and future formats for cell-based assays. Our ambition is to create an open and inspiring environment for networking between biologists and chemists, discussing the latest advancements and best practices in cell assay screening and their application for target identification, target validation and compound optimisation purposes.

Cell-based assays are utilised at all stages of drug discovery to explore disease mechanisms and to identify novel molecular therapeutics. To achieve this, the field is continuously looking for improvements in cell reagents, assay formats, and readouts to ensure disease-relevant contexts, aiming at improving translation to human physiology. Implementation of cell assays with more predictive translatability is much needed for improving success rates in drug discovery, and we are now entering an era where Artificial Intelligence and Machine Learning (AI/ML) can become the game changer. This meeting will explore how we continue to adapt to these challenges while working with unprecedented targets, novel biology, emerging drug modalities, the influence of international legislation and a drive for more sustainable drug discovery.

Event Link here.